All News

Conv3.jpg

EULAR 2025 - Day 1 Report

Jack Cush, MD

Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
GCA,woman

Secukinumab Use in Refractory Giant Cell Arteritis

Jack Cush, MD

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab.

Read Article
early.ra_.2.jpg

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia

Jack Cush, MD

A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

MTX Fails Knee OA (6.6.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Read Article
labs2.jpg

HLA-B27 Testing in Practice

Jack Cush, MD

Analysis of testing for human leukocyte antigen B27 (HLA-B27) in a teaching center shows HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications and primarily as a screening test. 

Read Article
autoimmune.disease

Autoimmunity Rising in Expectant Mothers

Jack Cush, MD

Lancet Rheumatology has published a UK study showing a significant increased in the number of expectant mothers beginning their pregnancies with autoimmune conditions.

Read Article
Prédiction of PsA from PsO. Stockholm cohort, n=672): •PsA incidence 21.1/1000 PY. •AUC 0.80 for both referral and prognostic models. •Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA. •Early identification feasible. Abstract OP0178 @RheumNow https://t.co/dxdChN6VZy

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Do the sites of clinical onset of PsA (i.e., swelling) correspond to those that, at the time of enrollment in the study, showed evidence of joint tenderness and/or ultrasound-detected alterations compatible with inflammation? Of 28 incident PsA cases, 68% had prior subclinical https://t.co/rAZJU6Va5x

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
29% of new-onset psoriasis pts in Stockholm cohort developed PsA over 9,255 person-years. Two prediction models (AUC 0.804) identify: ➡ who to refer ➡ who will progress Key predictors: HLA-B27, CRP, enthesitis, arthralgia. @RheumNow #EULAR2025 #OP0178:

Jiha Lee JihaRheum ( View Tweet)

Multimodal data using clinical histological and serological predictors in renal function in #sle nephritis. Using the AMP SLE data. Low baseline eGFR and histological damage predicted worsening renal function but not NIH activity index #POS0173 #EULAR2025 @RheumNow @andreafa https://t.co/Eh8dZXHRVX

Links:

Bella Mehta bella_mehta ( View Tweet)
Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA Erosions, Tenosynovitis and Synovitis non associated with D2T phenotype It’d be interesting to see if this could predict D2T evolution in early RA pts POS0185 https://t.co/faruOr3HhJ

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
In #SLE, #HCQ levels >1150 ng/ml ↑toxicity risk w/o added benefit. Levels 750-1150 ng/ml linked to ↓disease activity. CKD stage ≥3 doubled HCQ levels at same dose. Supports monitoring & dose adjustment in CKD to balance safety & efficacy. @RheumNow #EULAR2025 #OP0199

Mrinalini Dey DrMiniDey ( View Tweet)

BioDMARDs reduce polyimmunity in RA Danish Registry based cohort study 5 yrs follow up 25000+ pts Polyimmunity in csDMARDs treated group 2.2% vs. 1.7% in bioDMARDs group HR 0.74 Most frequent autoimmune thyroid disease POS0161 #EULAR2025 @RheumNow https://t.co/9T0mhoUuqs

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Leeds study of 223 ACPA+ Arthralgia pts w quant. MRI of hand showing tenosynovitis (34% at baseline) doubled the risk of progression to RA. Total tenosynovitis Volume = incr. RA risk #EULAR2025 POS0472 https://t.co/eT0wbhp1uN
Dr. John Cush RheumNow ( View Tweet)
Data from Dutch registry SpA-Net explored prevalence using new definitions for D2M axSpA. -Smoking and psoriasis were characteristics associated with D2M disease. -In the three variations explored, the lowest prevalence was observed in the variation based purely on objective https://t.co/h3f4ORQl0F

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Insights from the Gut-Joint Axis in axSpA: Findings from the DESIR cohort -Baseline biomarkers of bacterial translocation: PLTP (phospholipid transfer protein) and LPS evaluated. -In early axSpA baseline PLTP activity was associated with sacroiliac radiographic progression at 5

Adela Castro AdelaCastro222 ( View Tweet)

Biomarker data suggest TNFi non-responders in PsA exhibit upregulation of IL-17F gene signatures after treatment failure. Supports IL-17A/F blockade rationale with bimekizumab in TNFi-experienced patients Abstract#OP0091 @RheumNow . #EULAR2025 https://t.co/CWR6ArDRRW

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
🔬 Proud to present our poster at #EULAR2025! 📌 Serum KL-6 and IL-18 as Diagnostic and Prognostic Biomarkers in Systemic Sclerosis-Associated ILD: A 24-Month Cohort Study KL-6 and IL-18 show promising roles in tracking ILD progression and lung function decline in #SSc 📍F.136 https://t.co/woTMnTkRKY

Links:

Cristiana Sieiro Santos cristianasieiro ( View Tweet)
Got paraproteinemia? Here’s what to think about, from a rheumatology point of view. @RheumNow #EULAR2025 https://t.co/eu7Mi5yeum

Links:

David Liew drdavidliew ( View Tweet)
HLA-B27 Testing in Practice Analysis of testing for human leukocyte antigen B27 (HLA-B27) in a teaching center shows HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications and primarily as a screening test. https://t.co/IabqHyi0rl
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×